|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM107907461 |
| 003 |
DE-627 |
| 005 |
20231222144045.0 |
| 007 |
tu |
| 008 |
231222s2000 xx ||||| 00| ||eng c |
| 028 |
5 |
2 |
|a pubmed24n0360.xml
|
| 035 |
|
|
|a (DE-627)NLM107907461
|
| 035 |
|
|
|a (NLM)10866124
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Gorczynski, R M
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Synergy in induction of increased renal allograft survival after portal vein infusion of dendritic cells transduced to express TGFbeta and IL-10, along with administration of CHO cells expressing the regulatory molecule OX-2
|
| 264 |
|
1 |
|c 2000
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ohne Hilfsmittel zu benutzen
|b n
|2 rdamedia
|
| 338 |
|
|
|a Band
|b nc
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 29.06.2000
|
| 500 |
|
|
|a Date Revised 30.11.2018
|
| 500 |
|
|
|a published: Print
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Dendritic cells (DC), generated from C57BL/6 mouse bone marrow cells cultured with GM-CSF and IL-4 for 9 days, were engineered to express constitutively the cytokines TGFbeta, IL-10, and IL-12, using adenovirus vectors constructed using an E1-deleted replication-deficient recombinant adenovirus carrying the appropriate cDNA for the relevant cytokines (Ad-TGFbeta, Ad-IL-12, or Ad-IL-10). C3H mice receiving nontransduced DC or pretransplant infusion of DC-Ad-LacZ showed increased survival of C57BL/6 renal grafts relative to that of control nonimmunized mice. Transfusion of Ad-IL-12-transduced DC abolished this increased survival, leading to a graft survival equivalent to that of controls with no DC. Optimal graft survival was seen in the group receiving a mixture of DC transduced with constructs for both IL-10 and TGFbeta. There was a correlation between increased graft survival and both inhibition of the induction of CTL and enhancement of a polarization to produce type-2 cytokines (IL-4, IL-10, and TGFbeta) on antigen-specific restimulation in vitro. These effects were more pronounced following concomitant infusion of CHO cells transfected with a full-length cDNA for murine OX-2
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Research Support, Non-U.S. Gov't
|
| 650 |
|
7 |
|a Adjuvants, Immunologic
|2 NLM
|
| 650 |
|
7 |
|a Antigens, CD
|2 NLM
|
| 650 |
|
7 |
|a Antigens, Surface
|2 NLM
|
| 650 |
|
7 |
|a Cytokines
|2 NLM
|
| 650 |
|
7 |
|a Transforming Growth Factor beta
|2 NLM
|
| 650 |
|
7 |
|a Interleukin-10
|2 NLM
|
| 650 |
|
7 |
|a 130068-27-8
|2 NLM
|
| 650 |
|
7 |
|a antigens, CD200
|2 NLM
|
| 650 |
|
7 |
|a UQ4V77A8VA
|2 NLM
|
| 700 |
1 |
|
|a Bransom, J
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Cattral, M
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Huang, X
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Lei, J
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Xiaorong, L
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Min, W P
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Wan, Y
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Gauldie, J
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 95(2000), 3 vom: 12. Juni, Seite 182-9
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
| 773 |
1 |
8 |
|g volume:95
|g year:2000
|g number:3
|g day:12
|g month:06
|g pages:182-9
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 95
|j 2000
|e 3
|b 12
|c 06
|h 182-9
|